Private medical device firm, CloudCath gets approval from Food and Drugs Administration (FDA) for its CloudCath System. The data-driven, cloud-based, peritoneal dialysis (PD) patients are monitored through this platform. They have scheduled a limited launch of the CloudCath System through several clinics across the USA.

With state-of-the-art technology that fits effortlessly into the patient’s daily PD routine, the CloudCath System provides continuous analytics from the convenience of a patient’s home. To maintain the fluid requirement for home use of PD, the patients are monitored, and instant reports are sent to clinicians and patients. Patients and physicians may be alerted to the need for an examination days before symptoms appear, allowing patients to seek medical intervention, diagnosis, and treatment earlier.

“The opportunity to remotely and proactively manage our PD patients’ addresses a major obstacle to greater PD adoption. Today’s standard-of-care for patient monitoring is subjective. It relies on patients to self-monitor their dialysate fluid with either a decades-old “newspaper test,” the ability to read text through fluid drainage lines, or waiting for signs of pain and discomfort in the abdomen,” stated Glenn Chertow, MD, MDH, Professor of Medicine in Nephrology at Stanford University School of Medicine. “With the CloudCath solution, automated fluid analytics and real-time notifications will enable us to monitor and follow up with patients quickly, so they can stay home and on PD until a successful transplant.”

“FDA clearance of the CloudCath solution comes at a dynamic time in the dialysis market,” stated Aly ElBadry, CEO and Co-Founder of CloudCath. “With the 2019 Executive Order calling for increased use of at-home dialysis, CloudCath’s automated sensing and advanced PD care algorithm build a stronger connection between clinicians and patients to help dialysis providers meet these goals. We are excited to deliver new health insights and care algorithms that aim to eventually reduce hospitalizations and improve quality of life for PD patients.”